(Q36711606)

English

Therapeutic efficacy of fuzheng-huayu tablet based traditional chinese medicine syndrome differentiation on hepatitis-B-caused cirrhosis: a multicenter double-blind randomized controlled trail

scientific article published on 6 March 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Therapeutic efficacy of fuzheng-huayu tablet based traditional chinese medicine syndrome differentiation on hepatitis-B-caused cirrhosis: a multicenter double-blind randomized controlled trail (English)

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

multicenter clinical trial

0 references

liver cirrhosis

0 references

traditional Chinese medicine

1 reference

based on heuristic

inferred from title

object named as

traditional Chinese medicine

17 February 2024

author name string

Ya-Nan Song

1

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Ji-Jia Sun

2

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Yi-Yu Lu

3

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Lie-Ming Xu

4

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Yue-Qiu Gao

5

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Wei Zhang

6

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Xiao-Su Wang

7

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Dong-Ying Xue

8

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Qing-Shan Zheng

9

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Shi-Bing Su

10

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

publication date

6 March 2013

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Evidence-based Complementary and Alternative Medicine

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

2013

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

709305

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

copyright license

Creative Commons Attribution 3.0 Unported

1 January 2013

1 reference

April 2022 Public Data File from Crossref

copyright status

1 reference

April 2022 Public Data File from Crossref

Developing a 'traffic light' test with potential for rational early diagnosis of liver fibrosis and cirrhosis in the community

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3606729

30 September 2017

Applications of New Technologies and New Methods in ZHENG Differentiation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3606729

30 September 2017

Development of a bayesian forecasting method for warfarin dose individualization

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3606729

30 September 2017

[Investigation on indication of fuzheng huayu capsule against hepatic fibrosis and its non-invasive efficacy evaluation parameters: data analysis of liver biopsy of 50 patients with chronic hepatitis B before and after treatment].

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3606729

30 September 2017

Systematic review: The model for end-stage liver disease--should it replace Child-Pugh's classification for assessing prognosis in cirrhosis?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3606729

30 September 2017

Epidemiology and natural history of hepatitis B.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3606729

30 September 2017

Prognostic models including the Child-Pugh, MELD and Mayo risk scores--where are we and where should we go?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3606729

30 September 2017

Effects of Fuzheng Huayu 319 recipe on liver fibrosis in chronic hepatitis B.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3606729

30 September 2017

Treatment of depression--newer pharmacotherapies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3606729

30 September 2017

Hepatitis B: Evolving Epidemiology and Implications for Control

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3606729

30 September 2017

The efficacy of Liv-52 on liver cirrhotic patients: a randomized, double-blind, placebo-controlled first approach.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3606729

28 June 2018

A practical scoring system for predicting cirrhosis in patients with chronic viral hepatitis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3606729

5 September 2018

Fuzheng Huayu recipe and vitamin E reverse renal interstitial fibrosis through counteracting TGF-beta1-induced epithelial-to-mesenchymal transition

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3606729

5 September 2018

[Effects of Xuefu Zhuyu Oral Liquid on hemorheology in patients with blood-stasis syndrome due to coronary disease and their relationship with human platelet antigen-3 polymorphism].

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3606729

5 September 2018

Applying Fuzheng Huayu Gantang comprehensive therapeutic program for treatment of post-hepatitis B liver cirrhosis complicated with glyco-metabolic abnormality

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3606729

5 September 2018

Multicenter clinical study about the action of Fuzheng Huayu Capsule against liver fibrosis with chronic hepatitis B

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3606729

5 September 2018

[Construction of a therapeutic effect evaluation system for patients with primary liver cancer based on syndrome differentiation in traditional Chinese medicine].

1 reference

https://pubmed.ncbi.nlm.nih.gov/23533516

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Guideline for the diagnosis and treatment of liver fibrosis with integrative medicine]

1 reference

https://pubmed.ncbi.nlm.nih.gov/23533516

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver

1 reference

https://pubmed.ncbi.nlm.nih.gov/23533516

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1155/2013/709305

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36711606&oldid=2079842294"